Bisphosphonate Prodrugs

Jouko   J.   Vepsalainen

Abstract

Bisphosphonates (BP) are pyrophosphate analogs having a P-C-P backbone. The oral bioavailability of BPs is ca. 1%, due to high ionisation at physiological pH. Using the prodrug approach, oral absorption can be increased by masking one or more ionizable groups (clodronate, etidronate), or using a targeting carrier system (alendronate, pamitronate).

Keywords: pyrohosphate analogs, bisphosphonate, clodronate, etidronate

« Previous Next »

Rights & Permissions Print Cite

Current Medicinal Chemistry

Title: Bisphosphonate Prodrugs

Volume: 9 Issue: 12

Author(s): Jouko J. Vepsalainen

Affiliation:

Keywords: pyrohosphate analogs, bisphosphonate, clodronate, etidronate

Abstract: Bisphosphonates (BP) are pyrophosphate analogs having a P-C-P backbone. The oral bioavailability of BPs is ca. 1%, due to high ionisation at physiological pH. Using the prodrug approach, oral absorption can be increased by masking one or more ionizable groups (clodronate, etidronate), or using a targeting carrier system (alendronate, pamitronate).

Export Options

Export File:

RIS (for EndNote, Reference Manager, ProCite)

BibTeX

Text

Content:

Citation Only

Citation and Abstract

About this article

Cite this article as:

Vepsalainen J. Jouko, Bisphosphonate Prodrugs, Current Medicinal Chemistry 2002; 9 (12) . https://dx.doi.org/10.2174/0929867023369998

DOI https://dx.doi.org/10.2174/0929867023369998	Print ISSN 0929-8673
Publisher Name Bentham Science Publisher	Online ISSN 1875-533X

About this journal

Call for Papers in Thematic Issues

Submission closes on : 08 September, 2024

Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.

The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more

Guest Editor(s): Dr. Geir Bj?rklund

Submission closes on : 31 December, 2024

Approaches to the treatment of chronic inflammation

Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more

Guest Editor(s): Dr. Vladimir Rogovskii

Submission closes on : 10 November, 2024

Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications

The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more

Guest Editor(s): Dr. Igor A. Sobenin

Submission closes on : 14 July, 2024

Chalcogen-modified nucleic acid analogues

Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more

Guest Editor(s): Dr. Katarzyna Kulik